BAHA Osseointegrated denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for baha osseointegrated are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on BAHA Osseointegrated
## Why Cigna Denies BAHA (Bone-Anchored Hearing Aid) as Duplicate Therapy
A bone-anchored hearing aid (BAHA) is an osseointegrated auditory implant that transmits sound through direct bone conduction to the cochlea, bypassing the outer and middle ear. Cigna may deny a BAHA as "duplicate therapy" when its records indicate the patient already has a covered hearing device — such as a conventional acoustic hearing aid or a previously authorized BAHA — and the insurer concludes that the new device duplicates the function of the existing one. Bilateral BAHA requests (a second implant for the opposite side) and upgrade requests are the most common triggers.
## Why This Denial Is Appealable
Bilateral BAHAs serve a demonstrably distinct clinical function from a single device: binaural hearing restores sound localization and improves speech understanding in noise in ways a single device cannot replicate. If the second device addresses a different ear, a different hearing mechanism, or a condition the existing device cannot address, the "duplicate" characterization is clinically incorrect. The appeal must document the functional distinction and the audiological basis for the recommendation.
## Your Federal Appeal Rights
- Internal appeal: Under ACA §2719 and ERISA §503, you are entitled to full-and-fair internal review. The denial notice must specify which existing device Cigna considers duplicative.
- External review: Following a final internal denial, an accredited IRO can review the decision. The external-review window is generally approximately four months from the final internal denial.
- Expedited review: Available if delay would cause serious harm to hearing or communication function; document the urgency in writing.
## Documentation to Gather
1. Audiological evaluation — a complete, current audiogram with word-recognition scores performed by a licensed audiologist, documenting the type and severity of hearing loss in each ear. 2. Audiologist's device-recommendation letter — a signed letter explaining why the BAHA is recommended for this ear, why the existing device does not address the clinical need, and the expected functional benefit. 3. Existing-device trial documentation — evidence of any trial of the existing device on the affected ear, including outcome measures and the reason the device is inadequate. 4. Otolaryngologist or surgeon evaluation — documentation confirming candidacy for osseointegration and confirming that the hearing loss type (conductive, mixed, or single-sided deafness) is the specific indication for BAHA. 5. Prior-device records — records of any previously covered devices, to allow a factual comparison of function vs. the newly requested device.
## Criteria-Mapping Structure
Obtain Cigna's current published coverage policy for BAHA devices. Identify the criteria used to determine "duplicate therapy." For each criterion, provide a one-sentence answer citing the audiological record. Demonstrate that the requested device addresses a distinct clinical indication, a different ear, or a functional deficit the existing device cannot remediate.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →